High potency and controlled substances

Advancements in drug research, especially in oncology, inflammatory diseases, and antiviral compounds, have driven the development of new therapies with potent compounds and controlled substances.

Our specialized approach guarantees a seamless transition into clinical programs, backed by dedicated facilities and expert teams, covering the spectrum from pre-clinical exploration to small-scale commercial manufacturing.

Our platform seamlessly integrates the development of high-potency substances, the formulation of drug products, and advanced Solid State Research conducted in-house. This comprehensive approach ensures a streamlined process from inception to production, supported by state-of-the-art facilities and specialized centers.

In early drug development, we adopt a risk-based approach. This includes reviewing compound properties, conducting risk assessments, designing processes, and implementing mitigation strategies before manufacturing. We refine our approach with emerging data, focusing on long-term success through QbD principles for scalability, transferability, and manufacturing optimization.